Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 64Neoplasms 37Colorectal Neoplasms 35Neoplasm Metastasis 32Breast Neoplasms 31Ovarian Neoplasms 28Prostatic Neoplasms 27Pancreatic Neoplasms 27Recurrence 26Multiple Myeloma 25Melanoma 24Squamous Cell Carcinoma of Head and Neck 23Glioblastoma 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Lung Neoplasms 18Endometrial Neoplasms 18Triple Negative Breast Neoplasms 17Lymphoma, Large B-Cell, Diffuse 16Lymphoma, Non-Hodgkin 15Stomach Neoplasms 14Leukemia, Myeloid, Acute 14Colonic Neoplasms 14Burkitt Lymphoma 14Carcinoma, Renal Cell 13Small Cell Lung Carcinoma 12Glioma 12Uterine Cervical Neoplasms 11Sarcoma 11Lymphoma 11Head and Neck Neoplasms 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Infectious Mononucleosis × 30 days × Clear all
NCT05164094 2026-05-06

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

ModernaTX, Inc.

Phase 1/2 Active not recruiting
867 enrolled

Infectious Mononucleosis, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡